The U.S. Food and Drug Administration (FDA) has approved Optune Lua, a portable device that delivers tumor treating fields (TTFields) to help treat metastatic (advanced) non-small cell lung cancer (NSCLC) in adults who have not responded to platinum-based treatments. Worn on the body, Optune Lua produces alternating electric fields that disrupt the division of cancer cells, leading to their death. It’s used in combination with medication.

In clinical trials, Optune Lua was combined with PD-1/PD-L1 inhibitors or docetaxel. Results showed median overall survival was extended from 9.9 months to 13.2 months compared to drug treatments alone. Side effects, primarily skin irritation under the device, were generally mild to moderate, though some participants experienced more severe reactions.

A Novel Option for Advanced NSCLC Care

As the first device approved specifically for metastatic NSCLC, Optune Lua offers a unique approach that may improve survival without adding side effects that occur with traditional chemotherapy and immunotherapy. It can be used with existing treatments. People with advanced NSCLC can discuss with their health care providers whether Optune Lua could be an effective addition to their treatment strategy.

Learn about eight other recent advances in lung cancer treatment.

Find Your Team

On MyLungCancerTeam, the social network for people living with lung cancer and their loved ones, members come together to ask questions, give advice, and share their stories with others who understand life with lung cancer.

Would you try this type of device? Share your tips and experiences in a comment below, start a conversation on your Activities page, or find like-minded people in Groups.